UCB S.A.
UCB
Hisse Senetlerindeki Sıralama
#505
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Hisse Fiyatı
$251.46
Piyasa Değeri
$47.94B
Değişim (1 gün)
3.31%
Değişim (1 yıl)
-14.73%
Ülke
BE
Ticaret UCB S.A. (UCB)
Kategori
Healthcare
UCB S.A. (UCB) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 0.00
UCB S.A. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 0.00'dir. December 2023 sonunda şirketin 189.69M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
UCB S.A. (UCB) için 2002 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 189.89M | 0.10% |
| 2023 | 189.69M | 0.04% |
| 2022 | 189.62M | 0.34% |
| 2021 | 188.97M | -0.03% |
| 2020 | 189.04M | 0.97% |
| 2019 | 187.22M | -0.67% |
| 2018 | 188.48M | 0.11% |
| 2017 | 188.28M | -0.04% |
| 2016 | 188.37M | -1.94% |
| 2015 | 192.08M | 0.85% |
| 2014 | 190.46M | 4.56% |
| 2013 | 182.16M | 1.61% |
| 2012 | 179.28M | -6.39% |
| 2011 | 191.51M | 6.31% |
| 2010 | 180.15M | -0.02% |
| 2009 | 180.18M | 0.01% |
| 2008 | 180.17M | 0.00% |
| 2007 | 180.17M | 24.79% |
| 2006 | 144.38M | 0.60% |
| 2005 | 143.51M | -0.65% |
| 2004 | 144.45M | -1.02% |
| 2003 | 145.93M | -19.00% |
| 2002 | 180.17M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
